Trial Profile
A Phase I, open-label, single-dose study to evaluate the pharmacokinetics of Mirogabalin in patients with varying degrees of hepatic impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Sep 2018
Price :
$35
*
At a glance
- Drugs Mirogabalin (Primary)
- Indications Neuropathic pain; Pain; Postherpetic neuralgia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Daiichi Sankyo Inc
- 31 Aug 2018 Results published in the Clinical Drug Investigation
- 14 May 2018 New trial record